

28th March, 2016

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Fax No.:022-26598237 / 38
NSE Symbol: PANACEABIO

Bombay Stock Exchange Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Fax No.:022–22721919, 3121 BSE Scrip Code: 531349

Re.: Press Release - Panacea Biotec Launches - CABAPAN, a cost effective product for the treatment of metastatic Castration Resistant Prostrate Cancer (mCRPC)

Dear Sir,

We wish to inform you that the Company has introduced indigenously developed high quality Oncology product, CABAPAN (Cabazitaxel Injection), for treatment of *metastatic Castration Resistant Prostrate Cancer (mCRPC)*. Prostate is the second leading site of cancer amongst males with rising mortality rate in India.

CABAPAN has been developed by Company's State of the art Global Research and Development Center (GRAND) at Mumbai and manufactured at the Company's modern production facility complying with global cGMP, at Baddi, Himachal Pradesh.

A copy of the Press Release titled "Panacea Biotec Launches – CABAPAN, A Cost Effective product for the treatment of metastatic Castration Resistant Prostrate Cancer (mCRPC)" being issued to the media, etc. in this regard is enclosed for your kind reference and record please. Kindly acknowledge the receipt.

Thanking you, Sincerely yours, for Panacea Biotec Ltd.

Vinod Goel
Group CFO and Head Legal
& Company Secretary

Encl. As Above.

 Corporate Relationship Department Bombay Stock Exchange Ltd., 1st Floor, New Trading Ring, Rotundu Building, P J Towers, Dalal Street, Fort, Mumbai – 400 001 Fax No.22722037/39/41/61/3121/371

B1 Extn. /G3, Mohan Co-op Indl. Estate, Mathura Road, New Delhi -110044 Email: vinodgoel@panaceabiotec.com Phone: D.I.D. +91-11-4167 9015 Fax: +91-11-4167 9075



Innovation in support of life

Press Release:

For Immediate Distribution

Panacea Biotec Launches – CABAPAN A Cost Effective product for the treatment of metastatic Castration Resistant Prostrate Cancer (mCRPC)

New Delhi, 28th March, 2016: Panacea Biotec, India's 3rd largest biotechnology company introduces indigenously developed high quality Oncology product, CABAPAN (Cabazitaxel Injection), for treatment of *metastatic Castration Resistant Prostrate Cancer (mCRPC)*.


Prostate is the second leading site of cancer amongst males with rising mortality rate in India. With ever changing lifestyles, increased awareness, better diagnostic techniques and increased accessibility to medical treatment, more cases of Ca Prostate are being diagnosed.

CABAPAN has been developed by Panacea Biotec's State of the art Global Research and Development Center (GRAND), Mumbai and manufactured at modern production facility complying with global current Good Manufacturing Practices (cGMP), at Baddi, Himachal Pradesh.

CABAPAN aims to improve accessibility of this treatment for the benefit of patients at an affordable cost as part of our commitment to Government of India's "MAKE IN INDIA" mission. CABAPAN will be made available at one fifth of the current cost of treatment.

Commenting on the same, **Dr. Rajesh Jain**, Jt. Managing Director, Panacea Biotec Limited said, "Panacea Biotec has always endeavored to partner with Medical Practitioners in assisting to manage their patients better by introducing **New**, **Innovative and Good Quality products**.

Panacea Biotec will remain committed to its mission "Innovation in Support of Life" and continue to provide the Latest and Most Affordable preventive and therapeutic care to patients across the globe. The launch of CABAPAN reflects the hard work of Panacea Biotec's scientists who worked tenaciously for the development of this drug — added Dr. Rajesh Jain.





Innovation in support of life

Notes to the Editors

About Panacea Biotec

Panacea Biotec is one of India's leading research based Pharma-Biotech companies with established research, manufacturing and marketing capabilities. Panacea Biotec is one of the largest vaccine producer in India and has been amongst the top 40 biotechnology companies (Biospectrum - ABLE Survey, July 2014) and the top 60 pharmaceutical companies (AIOCD AWACS - MAT May 2014) in India. The product portfolio of Panacea Biotec includes innovative products in therapeutic areas of oncology, organ transplantation, nephrology, diabetes, osteoporosis, cardiovascular disease and pediatric immunization vaccines. Panacea Biotec is working on a robust pipeline of high barrier to entry generics and 505(b)(2)s, thus leveraging its capabilities in the areas of nanotechnology and platform drug delivery technologies like micro particles, liposomes, gastro-retentive systems. Panacea Biotec has introduced its products in 22 countries across the world including USA and Germany through a combination of strategic Panacea Biotec has research collaborations and direct presence in select geographies. collaborations with leading national and international research organizations and corporations. Panacea Biotec's state of the art manufacturing facilities for vaccines and pharmaceutical formulations comply with the US-FDA, UK-MHRA, SA-MCC and WHO-cGMP standards. The company has around 2,600 employees including around 125 scientists working across 4 R&D centers of the company.

For more information, please contact -

Mr. P. D. Karan

Vice President - Business Diversification & Corporate Communication

B-1 Extn. / A-27, Mohan Co-Operative Industrial Estate,

Mathura Road, New Delhi – 110044, INDIA

Tel: + 91 11 41679000 Extn. 1406, 41578080 (Direct)

Fax + 91 11 41578002

Mobile: + 91 9312693040, + 91 9810500539

Email: pdkaran@panaceabiotec.com
Web: www.panaceabiotec.comb

